ETF1

Across TCGA pan-cancer cohorts, ETF1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ETF1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ETF1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ETF1 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where ETF1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ETF1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.527	<.001	9	view →
CCRCC	All	II,III,IV	+0.168	<.001	9	view →
LSCC	Male	II,III,IV	+0.371	<.001	8	view →
PDAC	Female	II,III,IV	−0.856	<.001	7	view →
COAD	Female	III,IV	+0.245	<.001	7	view →
HNSC	Male	All	−0.155	<.001	6	view →
OV	All	All	+0.358	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ETF1–LUAD

Open the LUAD breakdown →